Critical shortage in BCG immunotherapy: How did we get here and where will it take us?

Author(s): Harvey, M; Chislett, B; Perera, M; Lawrentschuk, N; Bolton, D; Jack, G;
Details: Publication Year 2022-01,Volume 40,Issue #1,Page 1-3
Journal Title: Urologic Oncology: Seminars and Original Investigations
Publication Type: Commentary
Abstract: Intravesical Bacillus Calmette-Guerin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guerin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease.
Keywords: Adjuvants, Immunologic/*supply & distribution/therapeutic use; BCG Vaccine/*supply & distribution/therapeutic use; Humans; Immunotherapy; Urinary Bladder Neoplasms/drug therapy; Bacillus Calmette-Guerin vaccine; Bladder cancer; Tuberculosis
Department(s): Surgical Oncology
PubMed ID: 34750053
Publisher's Version: https://doi.org/10.1016/j.urolonc.2021.09.022
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-11-01 04:30:28

Last Modified: 2024-11-01 04:31:35